Compare · CLDX vs ORKA
CLDX vs ORKA
Side-by-side comparison of Celldex Therapeutics Inc. (CLDX) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLDX and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $4.89B, about 2.2x CLDX ($2.27B).
- Over the past year, CLDX is down 0.3% and ORKA is up 162.1% - ORKA leads by 162.4 points.
- ORKA has been more active in the news (3 items in the past 4 weeks vs 1 for CLDX).
- CLDX has more recent analyst coverage (22 ratings vs 11 for ORKA).
- Company
- Celldex Therapeutics Inc.
- Oruka Therapeutics Inc.
- Price
- $27.54-4.77%
- $71.99-2.53%
- Market cap
- $2.27B
- $4.89B
- 1M return
- -29.37%
- -26.35%
- 1Y return
- -0.29%
- +162.07%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 1
- 3
- Recent ratings
- 22
- 11
Celldex Therapeutics Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Latest CLDX
- Amendment: SEC Form SCHEDULE 13G/A filed by Celldex Therapeutics Inc.
- H.C. Wainwright reiterated coverage on Celldex Therapeutics with a new price target
- Celldex Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
- Celldex to Present at Upcoming Investor Conference
- SEC Form SCHEDULE 13G filed by Celldex Therapeutics Inc.
- SEC Form 10-Q filed by Celldex Therapeutics Inc.
- Celldex Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Celldex Reports Second Quarter Financial Results and Provides Corporate Update
- Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Latest ORKA
- SEC Form 4 filed by Oruka Therapeutics Inc.
- SEC Form 4 filed by Oruka Therapeutics Inc.
- Chief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,090,593 worth of shares (25,000 units at $83.62) as part of a pre-agreed trading plan (SEC Form 4)
- Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
- Senior Vice President, Finance Agarwal Arjun sold $51,035 worth of shares (533 units at $95.75) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 14,219 units (SEC Form 4)
- General Counsel Quinlan Paul T exercised 10,000 shares at a strike of $7.80 and sold $936,417 worth of shares (10,000 units at $93.64) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $734,145 worth of shares (7,947 units at $92.38) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 31,771 units (SEC Form 4) (for tax liability)
- Senior Vice President, Finance Agarwal Arjun sold $926,010 worth of shares (10,019 units at $92.43) as part of a pre-agreed trading plan and exercised 9,459 shares at a strike of $15.88, decreasing direct ownership by 4% to 14,752 units (SEC Form 4) (for tax liability)
- Chief Executive Officer Klein Lawrence Otto sold $234,681 worth of shares (2,452 units at $95.71), decreasing direct ownership by 0.26% to 923,128 units (SEC Form 4) to cover withholding tax
- General Counsel Quinlan Paul T sold $99,443 worth of shares (1,039 units at $95.71), decreasing direct ownership by 3% to 29,995 units (SEC Form 4) to cover withholding tax